{
  "meta": {
    "title": "M1_-_May_Mini_Test-1",
    "url": "https://brainandscalpel.vercel.app/m1-may-mini-test-1-fc34123f.html",
    "scrapedAt": "2025-11-30T12:44:53.415Z"
  },
  "questions": [
    {
      "text": "The sonography demonstrates:",
      "choices": [
        {
          "id": 1,
          "text": "Spalding sign"
        },
        {
          "id": 2,
          "text": "Roberts sign"
        },
        {
          "id": 3,
          "text": "Ball sign"
        },
        {
          "id": 4,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given ultrasonograph demonstrates<strong> overlapping skull bones, </strong>also known as<strong> Spalding sign.&nbsp;</strong></p>\n<p><strong>Option A: Spalding sign</strong></p>\n<ul>\n<li>The irregular overlapping of cranial bones on one another is due to liquefaction of brain and softening of ligamentous structures supporting the vault.</li>\n<li>It usually appears <strong>7 days after</strong> death</li>\n</ul>\n<p><strong>Option B: Roberts sign</strong></p>\n<ul>\n<li><strong>Earliest sign of IUD&nbsp;</strong>- seen within 12 hours of death</li>\n<li>The presence of gas shadow within the chambers of the heart and in large vessels of the fetus.</li>\n</ul>\n<p><strong>Option C: Blair-Hartley/Ball: sign&nbsp;</strong></p>\n<ul>\n<li>Hyperextension/hyperflexion of spine with crowding of ribs</li>\n<li>Usually<strong> seen 3-4 weeks after</strong> death</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td><strong>Sign</strong></td>\n<td><strong>Interval (After Death)</strong></td>\n</tr>\n<tr>\n<td>Robert sign (gas in great vessels)</td>\n<td>12h</td>\n</tr>\n<tr>\n<td>Spalding sign (overlapping of skull bones)</td>\n<td>1 week</td>\n</tr>\n<tr>\n<td>Blair-Hartley / Ball sign (hyperflexion / hyperextension of spine over ovecrowding of ribs)</td>\n<td>3-4 weeks</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d8747d037b9648cd92afe0ec5f64025e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0494",
      "difficulty": "easy"
    },
    {
      "text": "Unassisted(mature) pincer grasp is attained by the age of",
      "choices": [
        {
          "id": 1,
          "text": "4 months"
        },
        {
          "id": 2,
          "text": "6 months"
        },
        {
          "id": 3,
          "text": "9 months"
        },
        {
          "id": 4,
          "text": "12 months"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<hr><h3>Related Pearl: Developmental progression of the grasp</h3><p><strong>Ulnar palmar grasp</strong></p>\n<p>6 months: object is grasped by the ulnar side of the palm&nbsp;&nbsp;&nbsp;</p>\n<p><img class=\"WACImage SCX139599407\" src=\"data:image/jpeg;base64,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\" /><span id=\"{93b8e9bb-15bb-42f8-a3b3-6a3f62bc91c3}{207}\" class=\"WACAltTextDescribedBy SCX139599407\"></span><img class=\"WACImage SCX139599407\" src=\"data:image/jpeg;base64,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\" /></p>\n<p><br /><span id=\"{93b8e9bb-15bb-42f8-a3b3-6a3f62bc91c3}{207}\" class=\"WACAltTextDescribedBy SCX139599407\"></span></p>\n<p><strong>Radial palmar grasp </strong></p>\n<p>8-9 months: object is grasped by the radial side of the palm&nbsp;&nbsp;&nbsp;&nbsp;</p>\n<p><img class=\"WACImage SCX220550837\" src=\"data:image/jpeg;base64,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\" /><img class=\"WACImage SCX215536996\" src=\"data:image/jpeg;base64,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\" /></p>\n<p>&nbsp;</p>\n<p><strong>Immature pincer grasp </strong></p>\n<p>9 months: the object is secured between the adducted thumb and the extended index finger&nbsp;</p>\n<p><img class=\"WACImage SCX155962968\" src=\"data:image/jpeg;base64,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\" /><span id=\"{565e58e0-a27f-4721-bc7e-b094a18d1b82}{60}\" class=\"WACAltTextDescribedBy SCX57151736\"></span><img class=\"WACImage SCX57151736\" src=\"data:image/jpeg;base64,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\" /></p>\n<p>&nbsp;</p>\n<p><strong>Mature pincer grasp</strong></p>\n<p>12 months: the object is secured between the opposed thumb and the tip of the index finger.&nbsp;&nbsp;&nbsp;</p>\n<p><img class=\"WACImage SCX134039010\" src=\"data:image/jpeg;base64,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\" /><img class=\"WACImage SCX134039010\" src=\"data:image/jpeg;base64,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\" /></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0280",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following does not cause intravascular hemolysis?",
      "choices": [
        {
          "id": 1,
          "text": "Paroxysmal nocturnal hemoglobinuria"
        },
        {
          "id": 2,
          "text": "Thrombotic thrombocytopenic purpura"
        },
        {
          "id": 3,
          "text": "Infection"
        },
        {
          "id": 4,
          "text": "Thalassemia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Thalassemia</strong> causes <strong>extravascular</strong> hemolysis.</p>\n<p><strong>Causes </strong>of<strong> intravascular </strong>hemolysis<strong>:</strong></p>\n<ul>\n<li><span class=\"TextRun SCXW225898103\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW225898103\">Mechanical injury</span></span>\n<ul>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Trauma caused by cardiac valves&nbsp;</li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Microangiopathic&nbsp;hemolytic&nbsp;anaemias&nbsp;(hemolytic&nbsp;uremic syndrome,&nbsp;disseminated intravascular coagulation, <strong>thrombotic thrombocytopenic&nbsp;purpura&nbsp;</strong>)&nbsp;</li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">Repetitive physical trauma</li>\n</ul>\n</li>\n<li><span class=\"TextRun SCXW46333709\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW46333709\">Complement fixation (antibody-mediated destruction)</span></span>\n<ul>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Hemolytic&nbsp;disease of the&nbsp;newborn&nbsp;</li>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Transfusion reaction&nbsp;&nbsp;</li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">Drug-induced&nbsp;</li>\n</ul>\n</li>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\"><strong>Infections</strong> of red blood cells&nbsp;</span></span>\n<ul>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">Malaria </span></span></li>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">B</span></span><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW127641793\">abesiosis</span></span></li>\n</ul>\n</li>\n<li><span class=\"EOP SCXW127641793\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\"><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\">Exogenous toxic factors&nbsp;-&nbsp;</span></span></span><span class=\"EOP SCXW127641793\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\"><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\">C</span></span><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW261552469\">lostridial</span></span><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\">&nbsp;sepsis</span></span></span></li>\n</ul>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p class=\"ng-binding\"><strong>Causes </strong>of<strong> extravascular </strong>hemolysis<strong>:</strong></p>\n<ul>\n<li>Hereditary spherocytosis</li>\n<li><strong>Thalassemia</strong></li>\n<li>Sickle cell anaemia</li>\n</ul>\n<p><strong>Causes</strong> of <strong>both</strong> intravascular and extravascular:</p>\n<ul>\n<li>G6PD deficiency</li>\n<li>Autoimmune hemolytic anaemia</li>\n</ul>\n</div>\n</div><hr><h3>Related Pearl: Classification of Hemolytic Anemias</h3><p>Hemolytic anemias can be classified in 2 ways:</p>\n<p>1. Based on the <strong>type of defect</strong>:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Type</strong></td>\n<td><strong>Intracorpuscular Defects</strong></td>\n<td><strong>Extracorpuscular Factors</strong></td>\n</tr>\n<tr>\n<td>Hereditary</td>\n<td>\n<p>Hemoglobinopathies</p>\n<p>Enzymopathies</p>\n<p>Membrane-cytoskeletal defects</p>\n</td>\n<td>Familial (atypical) hemolytic uremic syndrome</td>\n</tr>\n<tr>\n<td>Acquired</td>\n<td>Paroxysmal nocturnal hemoglobinuria (PNH)</td>\n<td>\n<p>Mechanical destruction (microangiopathic)</p>\n<p>Toxic agents</p>\n<p>Drugs</p>\n<p>Infectious</p>\n<p>Autoimmune</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>2. Based on the <strong>sites</strong> of <strong>hemolysis:</strong></p>\n<p><strong>Intravascular</strong>hemolysis<strong>:</strong></p>\n<ul>\n<li><span class=\"TextRun SCXW225898103\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW225898103\">Mechanical injury</span></span>\n<ul>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Trauma caused by cardiac valves</li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Microangiopathic hemolytic anaemias (hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura)</li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"2\" aria-setsize=\"-1\" data-aria-posinset=\"3\" data-aria-level=\"1\">Repetitive physical trauma</li>\n</ul>\n</li>\n<li><span class=\"TextRun SCXW46333709\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW46333709\">Complement fixation (antibody-mediated destruction)</span></span>\n<ul>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\">Hemolytic disease of the newborn- ABO incompatibility </li>\n<li data-leveltext=\"%1.\" data-font=\"Calibri, sans-serif\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"1\">Transfusion reaction</li>\n<li data-leveltext=\"%1.\" data-font=\"\" data-listid=\"3\" aria-setsize=\"-1\" data-aria-posinset=\"4\" data-aria-level=\"1\">Drug-induced</li>\n</ul>\n</li>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">Infectionsof red blood cells</span></span>\n<ul>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">Malaria</span></span></li>\n<li><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW127641793\">B</span></span><span class=\"TextRun SCXW127641793\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW127641793\">abesiosis</span></span></li>\n</ul>\n</li>\n<li><span class=\"EOP SCXW127641793\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\"><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\">Exogenous toxic factors- c</span></span></span><span class=\"EOP SCXW127641793\" data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\"><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"SpellingError SCXW261552469\">lostridial</span></span><span class=\"TextRun SCXW261552469\" lang=\"EN-GB\" xml:lang=\"EN-GB\"><span class=\"NormalTextRun SCXW261552469\">sepsis</span></span></span></li>\n</ul>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p class=\"ng-binding\"><strong>Extravascular</strong>hemolysis<strong>:</strong></p>\n<ul>\n<li>Hereditary spherocytosis</li>\n<li>Thalassemia</li>\n<li>Sickle cell anemia</li>\n<li>Hemolytic disease of the newborn- Rh incompatibility</li>\n</ul>\n<p><strong>Both</strong>intravascular and extravascular hemolysis:</p>\n<ul>\n<li>G6PD deficiency</li>\n<li>Autoimmune hemolytic anemia</li>\n</ul>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0290",
      "difficulty": "medium"
    },
    {
      "text": "A 23-year-old patient with sickle cell anaemia presents with fever and malaise. IgM ELISA confirms a parvovirus B19 infection. Which of the following crises will you expect to see in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Aplastic"
        },
        {
          "id": 2,
          "text": "Sequestration"
        },
        {
          "id": 3,
          "text": "Vaso occlusion"
        },
        {
          "id": 4,
          "text": "Acute chest syndrome"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Aplastic crisis</strong> in sickle cell anaemia is caused by <strong>parvovirus B19</strong>.&nbsp;It is&nbsp;a transient arrest of erythropoiesis, usually triggered by an acute parvovirus infection. Parvovirus infects and kills red cell precursors. It occurs in sickle cell disease and other hemolytic anaemias.</p>\n<p><strong>Vaso-occlusive crises</strong> (pain crises) are episodes of <strong>hypoxic injury</strong> and <strong>infarction</strong> that cause severe pain in the affected region. The most commonly involved sites are the bones, lungs, liver, brain, spleen, and penis.&nbsp;<strong>Acute chest syndrome</strong> is a type of vaso-occlusive crisis involving the lungs. It typically presents with fever, cough, chest pain, and pulmonary infiltrates. Pulmonary inflammation may cause blood flow to become sluggish and &ldquo;spleenlike,&rdquo; leading to sickling and vaso-occlusion.&nbsp;</p>\n<p><strong>Sequestration crises</strong> occur in children with intact spleens. Massive entrapment of sickle red cells leads to rapid <strong>splenic enlargement</strong>, hypovolemia, and sometimes shock. Both sequestration crises and acute chest syndrome may be fatal and sometimes require prompt treatment with exchange transfusions.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0311",
      "difficulty": "easy"
    },
    {
      "text": "A farmer from Hoshiarpur, Punjab rushes his 10-year-old boy to the paediatric ER. The father complained of intractable nausea and diarrhoea in the child. On examination, the child has a garlicky odour and is severely dehydrated.  You notice neurologic manifestations along with nail and hair changes in the child. Which of the following mineral toxicities would you suspect?",
      "choices": [
        {
          "id": 1,
          "text": "Selenium toxicity"
        },
        {
          "id": 2,
          "text": "Chromium toxicity"
        },
        {
          "id": 3,
          "text": "Molybdenum toxicity"
        },
        {
          "id": 4,
          "text": "Iodine toxicity"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The clinical vignette is suggestive of acute <strong>selenium toxicity.</strong></p>\n<p>Selenium toxicity is characterised by nausea, diarrhoea, neurologic manifestations, nail and hair changes, and garlicky odour. It is commonly seen in areas where drinking water and the collated soil is extremely rich in selenium. In India, selenium toxicity is endemic to&nbsp;agricultural sites located in the states of <strong>Punjab and Haryana.&nbsp;</strong>The presentations are usually acute in nature rather than chronic.&nbsp;</p>\n<p><strong>Chromium toxicity</strong> (Option - B) is commonly seen only in adults with occupational exposure. Chromium is a <strong>pulmonary irritant</strong> and the symptoms are predominantly respiratory complaints similar to <strong>bronchitis</strong>. They also cause chronic <strong>allergic dermatitis</strong> and is <strong>carcinogenic</strong> too.&nbsp;</p>\n<p><strong>Molybdenum toxicity&nbsp;</strong>(Option C) is very rarely seen in humans. It manifests usually as <strong>acute diarrhoea</strong>.&nbsp;</p>\n<p><strong>Iodine toxicity&nbsp;</strong>(Option D) can range from <strong>mild GI illness</strong> to chronic thyroid dysfunction varying from <strong>hyperthyroidism</strong> to papillary thyroid carcinoma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0468",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following statements are true with respect to the WHO Baby-Friendly Hospital Initiative for small, sick, and preterm newborns (2020)?",
      "choices": [
        {
          "id": 1,
          "text": "Paladai feeding is indicated in very preterm infants with no suck-swallow-breath coordination"
        },
        {
          "id": 2,
          "text": "Finger-feeding is optimally indicated for short-term use and may improve breastfeeding rates at discharge"
        },
        {
          "id": 3,
          "text": "Feeding tubes are indicated only in neurologically compromised infants for long-term use"
        },
        {
          "id": 4,
          "text": "Bottle feeding can lead to overfeeding but has a reduced risk of aspiration in infants with immature suck-swallow-breathe reflex"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Finger-feeding</strong> is optimally indicated for <strong>short-term use</strong> and may <strong>improve breastfeeding rates</strong> at discharge. It is indicated in <strong>neurologically compromised</strong> and <strong>preterm</strong> infants for a <strong>short period</strong> of time.&nbsp;</p>\n<p><strong>Paladai feeding</strong> is indicated in <strong>preterm</strong>, <strong>late preterm,</strong>&nbsp;and <strong>term</strong> infants for <strong>supplementation</strong>. It is economic, cheap, and is <strong>easy</strong> to use and clean. It has a <strong>risk of aspiration</strong> and is a <strong>slower</strong> method of feeding.&nbsp;</p>\n<p><strong>Feeding tubes- orogastric or nasogastric tubes</strong> are an <strong>efficien</strong>t way of measuring intake. It is optimally used in <strong>very preterm</strong> infants with <strong>no suck-swallow-breathe coordination</strong> for <strong>long-term</strong> use. It requires <strong>frequent replacement.</strong></p>\n<p><strong>Bottle and teat feeding</strong>, though <strong>not recommended</strong> is an <strong>efficient</strong> way to feed. <strong>Slow-flow teats</strong> mimic breastfeeding and are preferred to rapid-flow teats. They allow <strong>overfeeding</strong> and there is a <strong>risk of aspiration</strong>.</p><p><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;World Breastfeeding Week is a global campaign celebrated 1-7 August every year. World Breastfeeding Week aims to highlight the huge benefits that breastfeeding can bring to both the health and welfare of babies, as well as for maternal health. The theme for this year is &ldquo;Support breastfeeding for a healthier planet&rdquo;&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">World Breastfeeding Week is a global campaign celebrated 1-7 August every year. World Breastfeeding Week aims to highlight the benefits that breastfeeding can bring to both the health and welfare of babies, as well as for maternal health. </span><span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;World Breastfeeding Week is a global campaign celebrated 1-7 August every year. World Breastfeeding Week aims to highlight the huge benefits that breastfeeding can bring to both the health and welfare of babies, as well as for maternal health. The theme for this year is &ldquo;Support breastfeeding for a healthier planet&rdquo;&quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\">The theme for the year 2022 is&nbsp;\"<strong>Step Up for Breastfeeding: Educate and Support</strong>\".</span></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0472",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most common trigger for hemolysis in patients with G6PD deficiency?",
      "choices": [
        {
          "id": 1,
          "text": "Infection"
        },
        {
          "id": 2,
          "text": "Drugs"
        },
        {
          "id": 3,
          "text": "Fava beans"
        },
        {
          "id": 4,
          "text": "Dehydration"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most common <strong>trigger</strong> for hemolysis in G6PD deficiency is<strong>infection.</strong>Viral hepatitis, pneumonia, and typhoid are the common infections that trigger hemolysis.</p>\n<p><strong>Episodic hemolysis</strong> (both intravascular and extravascular) is seen in G6PD deficiency. It is due to exposures that cause <strong>oxidative stress</strong>. The <strong>triggers</strong> include:</p>\n<ul>\n<li>Infections - oxygen-derived free radicals produced by activated leukocytes</li>\n<li>Drugs\n<ul>\n<li>Antimalarials -primaquine and chloroquine</li>\n<li>Sulfonamides</li>\n<li>Nitrofurantoin</li>\n</ul>\n</li>\n<li>Diet - fava bean</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0299",
      "difficulty": "medium"
    },
    {
      "text": "Complications of placenta previa include all except",
      "choices": [
        {
          "id": 1,
          "text": "Malpresentation"
        },
        {
          "id": 2,
          "text": "Premature labor"
        },
        {
          "id": 3,
          "text": "Rapid dilation of cervix"
        },
        {
          "id": 4,
          "text": "Retained placenta"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Complication of placenta previa <br /><strong>Antepartum:</strong> <br />o Malpresentation <br />o Cord prolapse <br />o Premature labor <br />o Early rupture of membranes <br /><strong>Intrapartum:</strong> <br />o Slow dilation of cervix <br />o Intrapartum hemorrhage <br />o Increased incidence of operative interference <br /><strong>Postpartum:</strong> <br />o Post partum hemorrhage <br />o Retained placenta </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0495",
      "difficulty": "medium"
    },
    {
      "text": "The following image shows the chest X-ray of a preterm neonate who was admitted to the NICU in view of severe respiratory distress.  What does this suggest?",
      "choices": [
        {
          "id": 1,
          "text": "Meconium  aspiration syndrome"
        },
        {
          "id": 2,
          "text": "Hyaline membrane disease"
        },
        {
          "id": 3,
          "text": "Transient tachypnoea of newborn"
        },
        {
          "id": 4,
          "text": "Bronchopulmonary  dysplasia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>From&nbsp;the given clinical picture of respiratory distress in a <strong>premature</strong> neonate and the X-ray findings of&nbsp;diffuse ground-glass (reticulo-granular) opacities with a characteristic&nbsp;white-out appearance<strong>,</strong>&nbsp;<strong>hyaline membrane disease</strong> (HMD) is the most likely diagnosis.</p>\n<p><strong>HMD</strong>, also known as neonatal <strong>Respiratory distress syndrome</strong>&nbsp;(RDS)&nbsp;is a relatively common condition resulting from insufficient production of surfactant that occurs in preterm neonates. Maternal diabetes, perinatal asphyxia, and multiple gestations are other known risk factors for the condition.&nbsp;Clinical features&nbsp;include tachypnea, chest retractions, expiratory grunting, and nasal flaring. The infant may or may not be cyanosed.&nbsp;</p>\n<p>X-ray features of HMD include:</p>\n<ul>\n<li>Air bronchogram sign</li>\n<li>Diffuse ground-glass opacities</li>\n<li>Obliteration of cardiac and diaphragmatic contours giving rise to 'white-out' lung (indicates severe disease)</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6b0e3f7efb9f4f75866b447a9463a883x720x304.JPEG\" alt=\"Explanation Image\"><p>&nbsp;</p>\n<p>Chest radiograph <strong>(A)</strong> shows reticulogranular opacities throughout both lungs with prominent air bronchograms. The cardiac silhouette is preserved and both lungs are hypoaerated.</p>\n<p>Chest radiograph <strong>(B)</strong> shows more severe changes. There is obliteration of the cardiac and diaphragmatic contours due to marked opacification, giving a complete <strong>&lsquo;white out&rsquo;</strong> <strong>appearance</strong></p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/1e4844d80d374529952ccd89c2225999.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0421",
      "difficulty": "easy"
    },
    {
      "text": "Purely ketogenic amino acid among the following is",
      "choices": [
        {
          "id": 1,
          "text": "Lysine"
        },
        {
          "id": 2,
          "text": "Leucine"
        },
        {
          "id": 3,
          "text": "Phenylalanine"
        },
        {
          "id": 4,
          "text": "Tryptophan"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Leucine</strong> is purely ketogenic amino acid.</p>\n<table>\n<tbody>\n<tr>\n<td>GLYCOGENIC</td>\n<td>KETOGENIC</td>\n<td>BOTH KETO AND GLYCOGENIC <strong>(mnemonic : L-PITT)</strong></td>\n</tr>\n<tr>\n<td>\n<p>Alanine <strong><em>(purely glycogenic if asked as a question)</em></strong></p>\n<p>Arginine</p>\n<p>Methionine</p>\n<p>Aspartate</p>\n<p>Proline</p>\n<p>Cysteine</p>\n<p>Serine</p>\n<p>Glutamate</p>\n<p>Threonine</p>\n<p>Glycine</p>\n<p>Valine</p>\n<p>Histidine</p>\n</td>\n<td>\n<p>Leucine <strong><em>(purely ketogenic)</em></strong> <strong>&nbsp;</strong></p>\n<p><strong>NOTE : even Lysine can be considered as purely ketogenic in a PGI format question</strong></p>\n</td>\n<td>\n<p>&nbsp;</p>\n<p>Lysine</p>\n<p>Phenylalanine</p>\n<p>Isoleucine</p>\n<p>Tryptophan</p>\n<p>Tyrosine&nbsp;</p>\n<p><strong>NOTE : Even threonine can be included in this column, for a PGI format question</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0496",
      "difficulty": "medium"
    },
    {
      "text": "Hunterian chancre is caused by",
      "choices": [
        {
          "id": 1,
          "text": "H.ducreyi"
        },
        {
          "id": 2,
          "text": "T.pallidum"
        },
        {
          "id": 3,
          "text": "Calymmatobacterium granulomatis"
        },
        {
          "id": 4,
          "text": "LGV"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<ul>\n<li>The primary lesion in syphilis is the chancre at the site of entry of the spirochete.</li>\n<li>Chancre is painless, indurated, avascular, circumscribed superficially ulcerated lesion. It is also known as <strong>hard chancre/Hunterian chancre</strong> named after John Hunter. The chancre is covered by a thick, glairy exudate rich in spirochetes.</li>\n</ul><hr><h3>Related Pearl: Comparison of Genital Ulcers</h3><table>\n<tbody>\n<tr>\n<td><span>&nbsp;</span></td>\n<td><span><strong>Genital herpes</strong></span></td>\n<td><span><strong>&nbsp;Syphilitic chancre (Hard chancre)</strong></span></td>\n<td><span><strong>Donovanosis/ granuloma inguinale</strong></span></td>\n<td><span><strong>Chancroid (soft chancre)</strong></span></td>\n<td><span><strong>LGV</strong></span></td>\n</tr>\n<tr>\n<td><span><strong>Incubation period</strong></span></td>\n<td><span>2-7 days</span></td>\n<td>\n<p><span>10-90 days&nbsp;</span></p>\n<p><span>Average: 21days</span></p>\n</td>\n<td><span>1-12 weeks</span></td>\n<td><span>1-14 days</span></td>\n<td><span>3 days - 6 weeks</span></td>\n</tr>\n<tr>\n<td><span><strong>Causative agent</strong></span></td>\n<td><span>HSV-2&gt;HSV-1</span></td>\n<td><em><span>Treponema pallidum</span></em></td>\n<td><em><span>Klebsiella granulomatis</span></em></td>\n<td><em><span>Hemophilus ducreyi</span></em></td>\n<td>\n<p><span><em>Chlamydia trachomatis</em></span><span>&nbsp;serovars L1,L2,L3</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Clinical presentation</strong></span></td>\n<td>\n<p><span>Cluster of vesicles on erythematous base.</span></p>\n<p><span> Painful and pruritic lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Single painless ulcer with a clean base and a firm raised border. </span></p>\n<p><span>Painless lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Painless papule or nodule erodes into beefy red granulomatous ulcer with rolled edges.</span></p>\n<p><span> No lymphadenopathy, pseudobubos are seen</span></p>\n</td>\n<td>\n<p><span>Painful ulcer (ducreyi makes you cry).</span></p>\n<p><span>Painful inguinal lymphadenopathy</span></p>\n</td>\n<td>\n<p><span>Painless genital ulcer.</span></p>\n<p><span>Painful inguinal lymphadenopathy</span></p>\n</td>\n</tr>\n<tr>\n<td><span><strong>Diagnosis&nbsp;</strong></span></td>\n<td><span>Tzanck preparation shows multinucleated giant cells, PCR</span></td>\n<td><span>Clinical diagnosis</span></td>\n<td><span>Donovan bodies on biopsy</span></td>\n<td><span>Clinical diagnosis</span></td>\n<td><span>Nucleic acid amplification tests</span></td>\n</tr>\n<tr>\n<td><span><strong>Treatment</strong></span></td>\n<td><span>Acyclovir/famcyclovir or valacyclovir</span></td>\n<td><span>Penicillin/Ceftriaxone</span></td>\n<td>\n<p><span>Azithromycin/</span><span>Doxycycline</span></p>\n</td>\n<td><span>Azithromycin/ceftriaxone</span></td>\n<td><span>&nbsp;Doxycycline</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0497",
      "difficulty": "hard"
    },
    {
      "text": "A diabetic patient who has developed chronic renal failure is prescribed a dipeptidyl-peptidase 4 (DPP4) inhibitor. No dose adjustment was done. Which of the following drugs was most likely prescribed to him?",
      "choices": [
        {
          "id": 1,
          "text": "Dulaglutide"
        },
        {
          "id": 2,
          "text": "Vildagliptin"
        },
        {
          "id": 3,
          "text": "Linagliptin"
        },
        {
          "id": 4,
          "text": "Pramlintide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Among the given options, the drug that was most likely prescribed to this patient is<strong>linagliptin. </strong>It is a <strong>DPP-4 inhibitor</strong> thatcan be <strong>safely used in renal failure.</strong>It is mainly <strong>excreted</strong> through the <strong>hepatobiliary route.</strong></p>\n<p>DPP4 inhibitors are orally acting novel drugs that act by the <strong>incretin pathway</strong> and stimulate <strong>insulin secretion</strong>. These drugs have significantly lesser chances of hypoglycemic side effects. These drugs are <strong>mainly eliminated unchanged by the kidneys,</strong> except<strong>Linagliptin</strong> which is eliminated by the<strong> hepatobiliary route</strong> and is therefore considered relatively safer in a patient with renal failure.</p>\n<p></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/feef159a142d4c04a39692ab831ad5fcx410x514.JPEG\" alt=\"Explanation Image\"><p></p>\n<p>Other options:</p>\n<p>Option A: Dulaglutide is safe in renal failure, but it is a<strong>GLP-1 analog.</strong></p>\n<p>Option B: <strong>Vildagliptin</strong> is a <strong>DPP-4 inhibitor</strong> but is excreted in the urine. The <strong>dose should be decreased</strong> in patients with <strong>renal failure</strong>.</p>\n<p>Option D: Pramlintide is an<strong>amylin analog </strong>and<strong></strong>can be used in moderate renal disease.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0498",
      "difficulty": "medium"
    },
    {
      "text": "In rugoscopy identification of a person is performed by taking prints from which part of hard palate",
      "choices": [
        {
          "id": 1,
          "text": "Anterior"
        },
        {
          "id": 2,
          "text": "Posterior"
        },
        {
          "id": 3,
          "text": "Middle"
        },
        {
          "id": 4,
          "text": "Lateral"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<ul>\n<li><strong><em>Rugoscopy</em></strong> (palatoprints) is the study of structural like rugae and grooves in the hard palate.In anterior part of hard palate the rugae and grooves are specific and permanant.</li>\n<li><strong><em>Chelioscopy </em></strong>is the study of lip prints</li>\n<li><strong><em>Podogram </em></strong>is the study of foot prints</li>\n<li>Ear prints and nose prints are also used for identification</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0499",
      "difficulty": "medium"
    },
    {
      "text": "The most common cause of anaemia in pregnancy is:",
      "choices": [
        {
          "id": 1,
          "text": "Iron deficiency"
        },
        {
          "id": 2,
          "text": "Acute blood loss"
        },
        {
          "id": 3,
          "text": "Megaloblastic"
        },
        {
          "id": 4,
          "text": "Anemia of inflammation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The two most common causes of anemia during pregnancy and the puerperium are iron deficiency and acute blood loss. Iron deficiency is more<br /><br /><strong>Classification of anemia:</strong> <br /> Physiological anemia of pregnancy <br /> Pathological <br />o Deficiency anemia (Isolated or combined):</p>\n<ul>\n<li>Iron deficiency</li>\n<li>Folic acid deficiency</li>\n<li>Vitamin B12 deficiency</li>\n<li>Protein deficiency</li>\n</ul>\n<p>o Hemorrhagic:</p>\n<ul>\n<li>Acute</li>\n<li>Chronic- Due to worm infestation, bleeding hemorrhoids</li>\n</ul>\n<p><br />o Hereditary:</p>\n<ul>\n<li>Thalassemia</li>\n<li>Sickle cell hemoglobinopathy</li>\n<li>Other hereditary hemolytic anemias</li>\n</ul>\n<p><br />o Anemia of inflammation/malignancy <br />o Aplastic/hypoplastic anemia</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0500",
      "difficulty": "easy"
    },
    {
      "text": "MAC value of an inhaled anesthetic is a measure of?",
      "choices": [
        {
          "id": 1,
          "text": "Duration of action"
        },
        {
          "id": 2,
          "text": "Potency"
        },
        {
          "id": 3,
          "text": "Speed of onset"
        },
        {
          "id": 4,
          "text": "Speed of recovery"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<ul>\n<li>Minimum alveolar concentration (MAC) of an inhaled anesthetic is the amount which is required to <strong>prevent movement</strong> in response to a <strong>defined noxious stimulus in 50% of subjects</strong>.</li>\n<li>MAC is a useful measure which allows comparisons of <strong>Potency</strong> between agents.</li>\n<li><strong>Lower the MAC value</strong>, lower is the concentration of anesthetic drug required which would imply the <strong>drug is more potent</strong>.</li>\n<li>Example: <strong>Nitrous oxide</strong> with a MAC value of 104 is the<strong> least potent</strong> inhaled anesthetic.<br /><strong>Methoxy flurane &ndash; MAC- 0.2, most potent.</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0501",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is an example of a natural Uncoupler?",
      "choices": [
        {
          "id": 1,
          "text": "2,4 Dinitrophenol"
        },
        {
          "id": 2,
          "text": "Oligomycin"
        },
        {
          "id": 3,
          "text": "Atractyloside"
        },
        {
          "id": 4,
          "text": "Thermogenin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<ul>\n<li>Uncouplers act by<strong> increasing the permeability of the mitochondrial membrane to ions</strong>, thereby collapsing the proton gradient established by allowing the H+ to pass across without going through the ATP synthase enzyme complex. This is how these substances &lsquo;uncouple&rsquo; electron flow through the respiratory complexes from ATP synthesis.</li>\n<li>Examples of Uncouplers:<br />1. <strong>Synthetic</strong> &ndash; 2, 4 dinitrophenol<br />2. <strong>Natural</strong> &ndash; Thermogenin: This is found naturally in the brown adipose tissue, whose function is heat generation, especially in new born.</li>\n<li><strong>Oligomycin</strong> is a competitive inhibitor of the Fo complex. By binding to the Fo domain of ATP synthase it closes the proton channel and hence prevents the reentry of protons into the matrix. By doing so, it stops the phosphorylation of ADP to ATP. It basically<strong> blocks oxidation and phosphorylation</strong> by stopping the flow of protons through ATP synthase enzyme complex.</li>\n<li><strong>Atractyloside</strong> is an inhibitor of oxidative phosphorylation.</li>\n<li>Inhibitors of ETC</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>COMPLEX</td>\n<td>INHIBITORS</td>\n</tr>\n<tr>\n<td>Complex I</td>\n<td>Rotenone, Amobarbital and Piercidin A</td>\n</tr>\n<tr>\n<td>Complex II</td>\n<td>TTFA, Carboxin and Malonate</td>\n</tr>\n<tr>\n<td>Complex III</td>\n<td>Antimycin A and BAL</td>\n</tr>\n<tr>\n<td>Complex IV</td>\n<td>Carbon monoxide, H2S, Cyanide and Sodium Azide</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0502",
      "difficulty": "medium"
    },
    {
      "text": "False regarding mirror syndrome",
      "choices": [
        {
          "id": 1,
          "text": "Polyhydramnios"
        },
        {
          "id": 2,
          "text": "Fetal hydrops"
        },
        {
          "id": 3,
          "text": "Preeclampsia"
        },
        {
          "id": 4,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Mirror Syndrome</strong> <br />An association between fetal hydrops and development of maternal edema in which the fetus mirrors the mother is attributed to Ballantyne. He called the condition triple edema because the fetus, mother, and placenta all became edematous. In a review case of mirror syndrome, it is found that approximately.</p>\n<ul>\n<li>90 percent of women had edema</li>\n<li>60 percent had hypertension,</li>\n<li>40 percent had proteinuria,</li>\n<li>20 percent had liver enzyme elevation, and</li>\n<li>Nearly 15 percent had a headache and visual disturbances.</li>\n</ul>\n<p>Based on these findings, it is reasonable to consider mirror syndrome a form of severe preeclampsia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0503",
      "difficulty": "medium"
    },
    {
      "text": "Owls eye inclusion bodies are seen in",
      "choices": [
        {
          "id": 1,
          "text": "Yellow fever"
        },
        {
          "id": 2,
          "text": "CMV"
        },
        {
          "id": 3,
          "text": "Adenovirus"
        },
        {
          "id": 4,
          "text": "Rabies virus"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Owl&rsquo;s eye inclusion bodies are intranuclear basophilic inclusion bodies seen in CMV infection.</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Inclusion bodies</strong></td>\n<td><strong>Virus</strong></td>\n</tr>\n<tr>\n<td>Negri bodies</td>\n<td>Rabies virus</td>\n</tr>\n<tr>\n<td>Torres bodies</td>\n<td>Yellow fever</td>\n</tr>\n<tr>\n<td>Bollinger bodies</td>\n<td>Fowl pox</td>\n</tr>\n<tr>\n<td>Guarnieri bodies</td>\n<td>Vaccinia</td>\n</tr>\n<tr>\n<td>Molluscum bodies</td>\n<td>Molluscum contagiosum</td>\n</tr>\n<tr>\n<td>Cowdry type A</td>\n<td>Herpes and yellow fever virus</td>\n</tr>\n<tr>\n<td>Cowdry type B</td>\n<td>Adenovirus, poliovirus</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f9c0bcdc99164c239b0a65bcc8bc2798x1280x949.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0504",
      "difficulty": "easy"
    },
    {
      "text": "True statement regarding inverse agonist is",
      "choices": [
        {
          "id": 1,
          "text": "Binds to the receptor and causes intended action"
        },
        {
          "id": 2,
          "text": "Binds to the receptor and causes opposite action"
        },
        {
          "id": 3,
          "text": "Binds to the receptor and causes no action"
        },
        {
          "id": 4,
          "text": "Binds to the receptor and causes submaximal action"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<ul>\n<li>According to the <strong>receptor occupation theory</strong>, the ability of a drug to bind to a receptor is its <strong>affinity</strong> and the ability to induce functional change in the receptor is designated as the<strong> intrinsic activity (IA)</strong> of the drug. These 2 properties are<strong> independent</strong> of each other. IA can be between -1 to +1.</li>\n<li><strong>Inverse agonists</strong> are drugs which have affinity for a receptor but the intrinsic activity opposite to that of an agonist i.e IA of an inverse agonist is -1.</li>\n<li><strong>Agonists</strong>: these have both affinity and IA of +1.</li>\n<li><strong>Partial agonists</strong>: have affinity but submaximal intrinsic activity. e.g pentazocine on &micro; opiod receptors.</li>\n<li><strong>Competitive Antagonists</strong>: have affinity but intrinsic activity 0.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0505",
      "difficulty": "easy"
    },
    {
      "text": "The ECG given below is seen in which of the following conditions:",
      "choices": [
        {
          "id": 1,
          "text": "Hypothermia"
        },
        {
          "id": 2,
          "text": "Hyperkalemia"
        },
        {
          "id": 3,
          "text": "STEMI"
        },
        {
          "id": 4,
          "text": "Hypokalemia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The blue arrows in the above ECG point to the <strong>J wave or the Osborn wave</strong> or the <strong>camel hump</strong> waves. This wave is seen in <strong>Hypothermia.</strong></p>\n<p><strong>Option B: </strong>Tall, tented T waves are seen in hyperkalemia.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f1fd1611de864bfc922f9d3a8474aa1ex801x792.PNG\" alt=\"Explanation Image\"><p><strong>Option C:</strong> STEMI shows ST segment elevation not J wave elevation on ECG.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c7fdd5c2e5aa406abb544de4617c74c6x1280x527.JPEG\" alt=\"Explanation Image\"><p><strong>Option D:</strong> U waves are seen in hypokalemia.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/edf56c3533894495b2e411d1df634af0x621x462.PNG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/b8f5d12369af44d8b089945a393ce5b5.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0506",
      "difficulty": "medium"
    },
    {
      "text": "An old cab driver whose livelihood depends on his driving is distressed. He complains that everything appears distorted and he perceives objects to smaller than their usual size. His anterior segment appears normal. Examination of the fundus reveals a honeycomb appearance of the macula. FFA is shown below. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Age related macular degeneration"
        },
        {
          "id": 2,
          "text": "Macular hemorrhage"
        },
        {
          "id": 3,
          "text": "Cystoid macular edema"
        },
        {
          "id": 4,
          "text": "Central Serous retinopathy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The image is that of fluorescein angiography showing the \"<strong>flower petal pattern,\"</strong>which is seen in <strong>cystoid macular edema (CME).</strong> The characteristic flower-petal appearance is due to the accumulation of dye in the <strong>outer plexiform layer</strong> and <strong>inner nuclear layer</strong> at the <strong>macula</strong></p>\n<p>The accumulation of fluid in the outer plexiform layer and the inner nuclear layer leads to<strong> retinal thickening</strong> at <strong>macula</strong> and <strong>loss</strong> of <strong>foveal depression</strong>, formation of cystic spaces <strong>(honey-comb macula). </strong>Risk factors include retinitis pigmentosa, uveitis, niacin, PGE2 analogues, epinephrine in aphakia, diabetic retinopathy, retinal venous occlusion and Irvin-Gass syndrome (CME post-cataract surgery).</p>\n<p>Symptoms may include <strong>blurring of vision, distortion,</strong> and <strong>micropsia</strong>.</p>\n<p>Therapeutic approaches for treating CME depend on the underlying etiology. This includes <strong>steroids,</strong> carbonic anhydrase inhibitors, anti-VEGF agents, PPV for associated vitreomacular traction.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/e545d67555cb41cd8d276cfc3bb17551.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0379",
      "difficulty": "medium"
    },
    {
      "text": "Von Gierkes disease is due to deficiency of which of the following enzymes?",
      "choices": [
        {
          "id": 1,
          "text": "Glucose-6-phosphatase"
        },
        {
          "id": 2,
          "text": "Branching enzyme"
        },
        {
          "id": 3,
          "text": "Debranching enzyme"
        },
        {
          "id": 4,
          "text": "Acid maltase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<ul>\n<li>Von Gierkes is a glycogen storage disorder which is caused due to deficiency of <strong>Glucose-6-phosphatase enzyme</strong>.</li>\n<li>The structural gene for glucose-6-phosphatase is located on <strong>chromosome 17</strong>. Von-Gierkes disease is inherited in an <strong>autosomal recessive</strong> manner.</li>\n<li>The biochemical hallmarks of the Von Gierke&rsquo;s disease are:<br />&bull; Hypoglycemia<br />&bull; Lactic acidosis<br />&bull; Hyperuricemia<br />&bull; Hyperlipidemia</li>\n</ul><hr><h3>Related Pearl: Glycogen Storage Diseases</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/782e85c36f0648698a222dca988adfabx1280x1863.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Enzyme deficiency</strong></p>\n</td>\n<td>\n<p><strong>Symptoms</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type 0</p>\n</td>\n<td>\n<p>Glycogen synthase</p>\n</td>\n<td>\n<p>Hypoglycemia</p>\n<p>Early death</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ia</p>\n<p><strong>Von Gierke's disease</strong></p>\n</td>\n<td>\n<p>Glucose-6- phosphatase</p>\n</td>\n<td>\n<p>Hepatomegaly and renomegaly&nbsp;due to glycogen accumulation</p>\n<p>Severe fasting hypoglycemia</p>\n<p>Growth failure</p>\n<p>Lactic acidosis</p>\n<p>Hyperuricemia</p>\n<p>Hyperlipidemia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type Ib</p>\n</td>\n<td>\n<p>Endoplasmic reticulum glucose-6- phosphate transporter</p>\n</td>\n<td>\n<p>Same as Von Gierke's disease</p>\n<p>Recurrent infections due to impaired neutrophil function</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type II</p>\n<p><strong>Pompe's disease</strong></p>\n</td>\n<td>\n<p>Lysosomal &alpha;1,4:1,6 glucosidase</p>\n<p>(Acid maltase)</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Death by age ~ 2 years (infantile variant)</p>\n<p>Cardiomegaly and heart failure</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type III</p>\n<p><strong>Cori's/Forbes disease</strong></p>\n<p>(Limit dextrinosis)</p>\n</td>\n<td>\n<p>Glycogen debranching enzyme</p>\n</td>\n<td>\n<p>Muscle weakness</p>\n<p>Fasting hypoglycemia</p>\n<p>Hepatomegaly due to accumulation of branched-chain polysaccharide (limit dextrins)</p>\n<p>Growth retardation</p>\n<p>Normal lactate and uric acid levels</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type IV</p>\n<p><strong>Andersen disease</strong></p>\n</td>\n<td>\n<p>Glycogen branching enzyme</p>\n</td>\n<td>\n<p>Failure to thrive</p>\n<p>Hepatomegaly due to accumulation of polysaccharides with few branch points</p>\n<p>Death at age ~ 5 years</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type V</p>\n<p><strong>McArdle disease</strong></p>\n</td>\n<td>\n<p>Muscle glycogen phosphorylase</p>\n</td>\n<td>\n<p>Exercise-induced cramps</p>\n<p>Renal failure due to rhabdomyolysis and myoglobinuria</p>\n<p>Second wind phenomenon</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VI</p>\n<p><strong>Her's disease</strong></p>\n</td>\n<td>\n<p>Liver glycogen phosphorylase</p>\n</td>\n<td>\n<p>Generally benign</p>\n<p>Mild hypoglycemia</p>\n<p>Hepatomegaly</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>GSD type VII</p>\n<p><strong>Tarui's disease</strong></p>\n</td>\n<td>\n<p>Muscle phosphofructokinase</p>\n</td>\n<td>\n<p>Exercise-induced muscle cramps and weakness</p>\n<p>Growth retardation</p>\n<p>Hemolytic anemia</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0507",
      "difficulty": "easy"
    },
    {
      "text": "A patient presents with abdominal colic and constipation. On examination, pallor and blue stippled lines on gums are observed. What is the most common mode of exposure to this particular toxicity?",
      "choices": [
        {
          "id": 1,
          "text": "Ingestion of paint"
        },
        {
          "id": 2,
          "text": "Inhalation of fumes"
        },
        {
          "id": 3,
          "text": "Absorption through skin"
        },
        {
          "id": 4,
          "text": "Drinking contaminated water"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>A patient presenting with constipation, pallor, and&nbsp;<strong>Burton's lines&nbsp;</strong>(blue stippled lines on gums), most likely has&nbsp;<strong>lead</strong> <strong>poisoning</strong>. The most common mode of exposure to lead toxicity is the&nbsp;<strong>inhalation of lead fumes</strong>.&nbsp;</p>\n<p>Lead poisoning occurs by lead exposure via the following modes:</p>\n<ul>\n<li>Inhalation- lead fumes in gasoline and petroleum products</li>\n<li>Ingestion- lead paint</li>\n<li>Absorption through the skin&ndash; seen only with organic leads</li>\n</ul>\n<p>The most toxic forms of lead are&nbsp;lead oxide, lead carbonate, and lead arsenate. The least toxic form is lead sulfide.</p><hr><h3>Related Pearl: Lead Poisoning/Plumbism/Saturnism</h3><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Lead Toxicity</strong></td>\n</tr>\n<tr>\n<td>Source of exposure</td>\n<td>\n<p>Occupational exposure</p>\n<p>Lead paint</p>\n</td>\n</tr>\n<tr>\n<td>Route of absorption</td>\n<td>\n<p>Children - GI tract</p>\n<p>Adults - Respiratory tract</p>\n</td>\n</tr>\n<tr>\n<td>Mechanism of action</td>\n<td>\n<ul>\n<li>Binds to sulfhydryl groups and inhibits\n<ul>\n<li>ALA dehydratase</li>\n<li>Ferrochelatase</li>\n</ul>\n</li>\n<li>Inhibits pyrimidine 5' nucleotidase</li>\n<li>Competes with <strong>calcium</strong></li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>Organs affected <strong>(acute</strong> toxicity)</td>\n<td>\n<p>GI tract, Bone marrow, Peripheral nerves</p>\n</td>\n</tr>\n<tr>\n<td>Organs affected <strong>(chronic</strong> toxicity)</td>\n<td>\n<p>CNS, Kidney</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Characteristic clinical findings</p>\n<p><strong>(ABCDEF)</strong></p>\n</td>\n<td>\n<p><strong>A - </strong>Anemia with basophilic stippling</p>\n<p><strong>B - </strong>Burtonian line (blue stippled line on gums)</p>\n<p><strong>C - </strong>Constipation and colic (abdominal pain)</p>\n<p><strong>D - </strong>Drop (wrist and foot drop) due to neuropathy</p>\n<p><strong>E - </strong>Encephalopathy-<strong>Mostly seen in infants</strong> presenting with severe ataxia, vomiting, lethargy, stupor, convulsions, and coma</p>\n<p><strong>F - Facial pallor (Earliest sign)</strong></p>\n</td>\n</tr>\n<tr>\n<td>Diagnosis</td>\n<td>Blood lead levels</td>\n</tr>\n<tr>\n<td>Treatment</td>\n<td>Calcium EDTA; succimer(DMSA)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0241",
      "difficulty": "medium"
    },
    {
      "text": "False statement about methotrexate",
      "choices": [
        {
          "id": 1,
          "text": "Inhibits DHFRase"
        },
        {
          "id": 2,
          "text": "Drug of choice for choriocarcinoma"
        },
        {
          "id": 3,
          "text": "Anti inflammatory"
        },
        {
          "id": 4,
          "text": "Protective to mucosa"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>&nbsp;Methotrexate is an inhibitor of dihydrofolate reductase (DHFRase)</strong>.<strong> It also inhibits thymidylate synthase.</strong></p>\n<p><strong>Uses of methotrexate:</strong></p>\n<ul>\n<li>Immunosuppressant</li>\n<li>Ectopic pregnancy</li>\n<li>Non-Hodgkin lymphoma</li>\n<li>DOC for choriocarcinoma</li>\n<li>Rheumatoid arthritis (anti-inflammatory)</li>\n<li>Crohn&rsquo;s disease</li>\n<li>Psoriasis</li>\n<li>Osteosarcoma</li>\n</ul>\n<p><br /><strong>Adverse effects:</strong></p>\n<ul>\n<li>Hepatotoxic</li>\n<li>Nephrotoxic</li>\n<li>Mucositis</li>\n<li>Diarrhoea</li>\n<li>Bone marrow suppression</li>\n<li>Pulmonary fibrosis</li>\n</ul>\n<p><br />&bull; Toxicity of methotrexate to normal cells can be reduced by administration of folinic acid or leucovorin or citrovorum factor.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0508",
      "difficulty": "easy"
    },
    {
      "text": "Sputum smear becomes positive on ZN staining when the concentration of TB bacillus in the sample are more than",
      "choices": [
        {
          "id": 1,
          "text": "100 Bacilli /ml"
        },
        {
          "id": 2,
          "text": "1000 Bacilli/ml"
        },
        {
          "id": 3,
          "text": "10000 Bacilli/ml"
        },
        {
          "id": 4,
          "text": "100000 Bacilli /ml"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>&nbsp;For the sputum sample to become positive on ZN staining there must be a minimum of 10000 Bacilli/ml. On ZN staining the decolorizer used is 25% is sulphuric acid, bacilli appear <strong>rod shaped with beaded appearance </strong>(which is due to mycolic acid in the cell wall)</p>\n<p><strong>Grading of smears on ZN stain</strong></p>\n<table>\n<tbody>\n<tr>\n<td>0</td>\n<td>No Bacilli/100 oil immersion fields</td>\n</tr>\n<tr>\n<td>Scanty</td>\n<td>1-9 Bacilli /100 oil immersion fields</td>\n</tr>\n<tr>\n<td>1+</td>\n<td>10-99 Bacilli /100 oil immersion fields</td>\n</tr>\n<tr>\n<td>2+</td>\n<td>1-10 Bacilli /oil immersion field</td>\n</tr>\n<tr>\n<td>3+</td>\n<td>&gt;10 Bacilli /oil immersion field</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0509",
      "difficulty": "medium"
    },
    {
      "text": "5 day fever is caused by",
      "choices": [
        {
          "id": 1,
          "text": "Bartonella henslae"
        },
        {
          "id": 2,
          "text": "Bartonella quintana"
        },
        {
          "id": 3,
          "text": "Bartonella bacilliformis"
        },
        {
          "id": 4,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>5 day fever or trench fever is casued by<strong> B.quintana</strong><br />&bull; It is transmitted by <strong>louse &ndash; pediculis hominis corporis</strong><br />&bull; No animal reservoir known<br />&bull; It can grow in a cell free culture media such as blood agar</p>\n<p>Diseases transmitted by louse include</p>\n<ul>\n<li>Epidemic typhus</li>\n<li>Trench fever/ 5 day fever</li>\n<li>Epidemic relapsing fever</li>\n<li>Pediculosis </li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0510",
      "difficulty": "medium"
    },
    {
      "text": "In a negatively skewed distribution, which of the following statements is true?",
      "choices": [
        {
          "id": 1,
          "text": "Mean < Median < Mode"
        },
        {
          "id": 2,
          "text": "Mean = Mode = Median"
        },
        {
          "id": 3,
          "text": "Mean > Median > Mode"
        },
        {
          "id": 4,
          "text": "Mean > Median < Mode"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In negatively skewed distribution Mean&lt;Median&lt;Mode.</p>\n<p>The <strong>normal distribution curve</strong> is a <strong>symmetric</strong> curve, also called the <strong>Bell curve</strong>. In the normal distribution curve, the mean = median = mode. The distribution can be skewed due to either abnormally low or abnormally high values. There are two types of skewing</p>\n<ul>\n<li><strong>Negative or left skewed:</strong> Mean &lt; Median &lt; Mode</li>\n<li><strong>Positive or right skewed:</strong> Mean &gt; Median &gt; Mode</li>\n</ul><hr><h3>Related Pearl: Mean, Median, Mode in Different Distribution Shapes</h3><ul>\n<li>The relationship between the mean, median and mode depends upon the distribution.</li>\n<li>In a <strong>unimodal symmetrical </strong>distribution like a <strong>normal distribution</strong>, all the <strong>three measures</strong> are approximately the<strong> same</strong>, as shown in Figure (2) in the following image, i.e., <strong>mean = median = mode.</strong></li>\n<li>Figure (3) in the following image shows a <strong>positively skewed</strong> distribution in which the <strong>longer tail </strong>is towards the<strong> positive direction</strong>. In this, the mean will be larger than the median and mode, i.e., <strong>mean &gt; median &gt; mode.</strong></li>\n<li>Figure (1) in the following image shows a <strong>negatively skewed</strong> distribution in which the <strong>longer tail </strong>is towards the<strong> negative direction</strong>. In this, the mean will be smaller than the median, i.e., <strong>mean &lt; median &lt; mode.</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d79321686162499ca8b9174d58e8f7aex1280x2893.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td>\n<p>Unimodal <strong>symmetrical distribution</strong></p>\n</td>\n<td>\n<p><strong>Mean = Median = Mode</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Positively (right) skewed</strong> distribution</p>\n</td>\n<td>\n<p><strong>Mean &gt; Median &gt; Mode</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Negatively (left) skewed</strong> distribution</p>\n</td>\n<td>\n<p><strong>Mean &lt; Median &lt; Mode</strong></p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li>As seen in the figures above, in any distribution curve, the <strong>mode </strong>is generally the<strong> highest point</strong>. The <strong>mean</strong> will be pulled up or down <strong>based </strong>on the<strong> values</strong> in the distribution. The <strong>median </strong>will lie<strong> between</strong> the <strong>mode</strong> and <strong>mean</strong> and <strong>divide</strong> the distribution in two<strong> equal halves</strong> under the curve.</li>\n<li>A <strong>bimodal distribution</strong> will have <strong>two high</strong> points as shown in the image below.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/25c3b8cb808949c2891e9d098cd1ab54x1280x1007.JPEG\" alt=\"Pearl Image\"><ul>\n<li>Mathematically, the relationship between mode, median and mean in <strong>asymmetrical</strong> distributions can be given as:<br /><strong>Mode = 3 median  2 mean</strong> (or) <strong>Mean =  (3 median  mode).</strong></li>\n<li><strong>Outlier </strong>is the statistical term used for an <strong>observation </strong>or value that is<strong> very distant </strong>from<strong> other </strong>observations in the distribution.</li>\n<li>In a distribution with <strong>outliers</strong>, <strong>preferred </strong>measure of central tendency is the<strong>median</strong>.</li>\n<li><strong>Mode </strong>is <strong>least </strong>affected<strong> by outliers</strong> but <strong>mean </strong>is the <strong>most</strong> affected out of all the measures of location.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0511",
      "difficulty": "medium"
    },
    {
      "text": "All of the following are true about HMG coA reductase inhibitors except",
      "choices": [
        {
          "id": 1,
          "text": "CNS accumulation of simvastatin and lovastatin is high and less for pravastatin and fluvastatin"
        },
        {
          "id": 2,
          "text": "Simvastatin is rapidly metabolised and pravastatin is least metabolised"
        },
        {
          "id": 3,
          "text": "Bioavailability is minimally modified when pravastatin is taken with food"
        },
        {
          "id": 4,
          "text": "Fibrinogen levels are increased by pravastatin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<ul>\n<li>Fibrinogen levels are <strong>decreased by pravastatin</strong> not increased.</li>\n<li>Among the statins Pravastatin has got some special features.<br />Pravastatin:</li>\n<li>Minimum drug interactions (not metabolized by microsomal enzymes)</li>\n<li>Minimum food interactions (absorption of all other statins are increased by food)</li>\n<li>Minimum risk of myopathy</li>\n<li>Minimum CNS penetration</li>\n<li>Minimize (decrease) fibrinogen level</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0512",
      "difficulty": "hard"
    },
    {
      "text": "Lymphangioleiomyomatosis (LAM) is seen in",
      "choices": [
        {
          "id": 1,
          "text": "Prepubertal males"
        },
        {
          "id": 2,
          "text": "Post menopausal females"
        },
        {
          "id": 3,
          "text": "Pre menopausal females"
        },
        {
          "id": 4,
          "text": "Post pubertal males and females"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Lymphangioleiomyomatosis (LAM) is seen in premenopausal females. ILD (Interstitial lung disease), in general, occur more commonly in women.</p>\n<p><br /><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Gender predisposition in ILDs</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Women</strong></td>\n<td><strong>Men</strong></td>\n</tr>\n<tr>\n<td>Exclusively in premenopausal women:LAM Pulmonary involvement in Tuberous Sclerosis</td>\n<td>Pneumoconiosis (due to occupational exposure to asbestos, beryllium, and silica)</td>\n</tr>\n<tr>\n<td>ILDs in association with CTD(connective tissue disorder) (except ILD is associated with rheumatoid arthritis)</td>\n<td>ILD is associated with rheumatoid arthritis&nbsp;</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>IPF (Idiopathic pulmonary fibrosis)</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>Pulmonary LCH (Langerhans cell histiocytosis)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Lymphangioleiomyomatosis</p>\n<p>Seen in young women with recurrent pneumothorax or chylous effusion. The disease accelerates during pregnancy and abates after oophorectomy. <strong>HRCT shows thin-walled cysts</strong> surrounded by normal lung parenchyma. It is associated with meningioma. <strong>Marker: HMB-45.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0513",
      "difficulty": "medium"
    },
    {
      "text": "Match the types of hemoglobin with their globin chains.<div class='question-desc-html'><table>\n<tbody>\n<tr>\n<td><strong>Hemoglobin</strong></td>\n<td><strong>Globin chains</strong></td>\n</tr>\n<tr>\n<td>1. HbF</td>\n<td>A. &alpha; and &beta;</td>\n</tr>\n<tr>\n<td>2. HbA</td>\n<td>B. &alpha; and &delta;</td>\n</tr>\n<tr>\n<td>3. HbA2</td>\n<td>C. &alpha; and &gamma;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div>",
      "choices": [
        {
          "id": 1,
          "text": "1-B, 2-A, 3-C"
        },
        {
          "id": 2,
          "text": "1-C, 2-A, 3-B"
        },
        {
          "id": 3,
          "text": "1-C, 2-B, 3-A"
        },
        {
          "id": 4,
          "text": "1-A, 2-B, 3-C"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The types of hemoglobin along with their globin chains are:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Hemoglobin</strong></td>\n<td><strong>Components</strong></td>\n</tr>\n<tr>\n<td>HbF</td>\n<td>&alpha;2&gamma;2</td>\n</tr>\n<tr>\n<td>HbA</td>\n<td>&alpha;2&beta;2</td>\n</tr>\n<tr>\n<td>HbA2</td>\n<td>&alpha;2&delta;2</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>The image given below shows the graphical representation of the globin chain synthesis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/58cda96961ec4c02aedddc913b5529a5x1280x1121.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0302",
      "difficulty": "easy"
    },
    {
      "text": "Secretion of casein by mammary gland cells is an example of",
      "choices": [
        {
          "id": 1,
          "text": "Merocrine secretion"
        },
        {
          "id": 2,
          "text": "Holocrine secretion"
        },
        {
          "id": 3,
          "text": "Apocrine secretion"
        },
        {
          "id": 4,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<ul>\n<li>Mammary gland cells secrete &nbsp;<strong>milk protein</strong>, casein, <strong>by</strong> <strong>merocrine secretion</strong>.</li>\n<li><strong>Milk fat</strong> is secreted by <strong>apocrine secretion</strong></li>\n<li>In merocrine secretion, secretions are initially packaged into membrane-bound vesicles which then fuse with the plasma membrane to release their contents to the exterior. It is by far the <strong>most common secretory mechanism</strong>.</li>\n<li>In apocrine glands, some of the apical cytoplasm is pinched off with the contained secretions, which are stored in the cell as membrane-free droplets.</li>\n<li>In holocrine glands, cells first fill with secretory products, after which the entire cell disintegrates to liberate the accumulated mass of secretion into the adjacent duct.</li>\n<li>Glands such as<strong> simple sweat glands of skin</strong>, where ions and water are actively transported from plasma as an exudate, were once classified as eccrine glands. They are now known to synthesize and secrete small amounts of protein by a merocrine mechanism, and have been<strong> reclassified as</strong> <strong>merocrine glands.</strong></li>\n<li><strong>Type of Gland and location:</strong>\n<table>\n<tbody>\n<tr>\n<td>Apocrine glands&nbsp;</td>\n<td>Secretion of milk fat by mammary gland cells, specialized&nbsp;sweat glands in the axilla&nbsp;and anogenital regions of the body.&nbsp;</td>\n</tr>\n<tr>\n<td>Merocrine glands&nbsp;</td>\n<td>Secretion of milk protein, sweat glands previously classified as eccrine glands&nbsp;</td>\n</tr>\n<tr>\n<td>Holocrine glands&nbsp;</td>\n<td>sebaceous glands in the skin&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0514",
      "difficulty": "hard"
    },
    {
      "text": "All of the following drugs are used for chronic prophylaxis of migraine except:",
      "choices": [
        {
          "id": 1,
          "text": "Propranolol"
        },
        {
          "id": 2,
          "text": "Amitriptyline"
        },
        {
          "id": 3,
          "text": "Sumatriptan"
        },
        {
          "id": 4,
          "text": "Valproate"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Sumatriptan</strong> has <strong>no role in the chronic prophylaxis </strong>of migraine. It is <strong>only used</strong> <strong>for</strong> the treatment of an <strong>acute episode</strong>.</p>\n<p>Medication for <strong>chronic prophylaxis</strong> of migraine should be <strong>considered</strong> <strong>in</strong> <strong>patients</strong> <strong>with four or more attacks per month</strong>. The <strong>medications</strong> that are <strong>beneficial</strong> <strong>include</strong>:</p>\n<ul>\n<li>Beta-blockers: <strong>propranolol</strong>, metoprolol</li>\n<li>Anti-depressants: <strong>amitriptyline</strong>, venlafaxine</li>\n<li>Anti-convulsants: <strong>valproate</strong>, <strong>topiramate</strong></li>\n<li><strong>CGRP antagonists</strong> (monoclonal antibodies): eptinezumab, erenumab, fremanezumab, galcanezumab</li>\n<li>Others: <strong>flunarizine</strong>, <strong>candesartan</strong>, memantine</li>\n</ul>\n<p><strong>Migraine</strong> is a primary headache disorder characterized by <strong>episodic headaches</strong>. The patients present with a <strong>unilateral, throbbing type of headache</strong>. The headache is preceded by a <strong>prodrome</strong> period characterized by <strong>mental fatigue</strong>, <strong>mood changes</strong>, and <strong>aura</strong> in the form of visual disturbances <strong>(zigzag lines in the visual field)</strong>. The headache is associated with <strong>nausea</strong>, <strong>photophobia,</strong> and <strong>phonophobia</strong>.</p>\n<p><strong>Acute treatment</strong> of migraine is done with <strong>paracetamol</strong> and <strong>NSAIDs</strong> (naproxen, diclofenac). If this treatment does not bring relief, <strong>triptans</strong> such as <strong>sumatriptan</strong> or <strong>rizatriptan</strong> are given. They are <strong>agonists at 5HT<sub>1B/1D </sub>receptors</strong> and cause vasoconstriction in the intracranial blood vessels. Other drugs that can be given for the acute treatment of migraine are <strong>calcitonin-gene-related peptide (CGRP) receptor antagonists</strong> <strong>rimegepant</strong> and <strong>ubrogepant</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0515",
      "difficulty": "medium"
    },
    {
      "text": "Injury to median nerve at the wrist is tested by",
      "choices": [
        {
          "id": 1,
          "text": "Contraction of flexor pollicis brevis"
        },
        {
          "id": 2,
          "text": "Loss of sensation of the palm"
        },
        {
          "id": 3,
          "text": "Contraction of abductor pollicis brevis"
        },
        {
          "id": 4,
          "text": "Loss of sensation on the ring finger"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<ul>\n<li><strong>Abductor pollicis brevis</strong> is the one small muscle of the hand that is <strong>consistently innervated by the median nerve</strong>.</li>\n<li>Flexor pollicis brevis cannot be tested separately as flexion of MCP joint can be produced by FPL as well.</li>\n<li>Sensation of lateral aspect of palm by palmar cutaneous branch is given in distal forearm, hence spared by injury at the wrist.</li>\n<li>Ring finger has sensory supply from median and ulnar nerve.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0516",
      "difficulty": "medium"
    },
    {
      "text": "Primordial germ cells are derived from",
      "choices": [
        {
          "id": 1,
          "text": "Epiblast"
        },
        {
          "id": 2,
          "text": "Hypoblast"
        },
        {
          "id": 3,
          "text": "Genital ridge"
        },
        {
          "id": 4,
          "text": "Endoderm"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Primordial germ cells are derived from theepiblast/ primitive ectoderm in the 2ndweek of Intrauterine life.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0517",
      "difficulty": "medium"
    },
    {
      "text": "ANCA positivity is seen in",
      "choices": [
        {
          "id": 1,
          "text": "Cryoglobulinemic vasculitis"
        },
        {
          "id": 2,
          "text": "Hypersensitivity vasculitis"
        },
        {
          "id": 3,
          "text": "Microscopic polyangiitis"
        },
        {
          "id": 4,
          "text": "Cogans syndrome"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>ANCA (Antineutrophilic cytoplasmic antibody) positivity is seen in certain types of vasculitis. There are 2 types: c ANCA and p ANCA &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>c ANCA</strong></td>\n<td><strong>p ANCA</strong></td>\n</tr>\n<tr>\n<td><strong>Location of ANCA</strong></td>\n<td>Cytoplasmic</td>\n<td>Perinuclear</td>\n</tr>\n<tr>\n<td><strong>Target antigen</strong></td>\n<td>Proteinase 3</td>\n<td>Myeloperoxidase</td>\n</tr>\n<tr>\n<td><strong>Positive in:</strong></td>\n<td>Wegener&rsquo;s granulomatosis(Granulomatosis with polyangiitis)</td>\n<td>Microscopic polyangiitisChurg-Strauss syndrome</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0518",
      "difficulty": "easy"
    },
    {
      "text": "Mucosal neuromas, marfanoid habitus, medullated corneal nerve fibres and megacolon are conditions associated with which of the following syndromes?",
      "choices": [
        {
          "id": 1,
          "text": "MEN 1"
        },
        {
          "id": 2,
          "text": "MEN 2A"
        },
        {
          "id": 3,
          "text": "MEN 3"
        },
        {
          "id": 4,
          "text": "MEN 4"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>MEN 2B is also called MEN 3. It arises from a mutation in RET protoncogene and is characterized by:<br />&bull; Medullary thyroid cancer (&gt;90%)<br />&bull; Pheochromocytoma (&gt;50%)<br />&bull; Associated abnormalities;<br />&bull; Mucosal neuromas<br />&bull; Marfanoid habitus<br />&bull; Medullated corneal nerve fibres<br />&bull; Megacolon</p><hr><h3>Related Pearl: MEN 2 Syndrome Features</h3><p><strong>MEN 2A</strong></p>\n<ul>\n<li>Known as <strong>Sipple&rsquo;s</strong> syndrome</li>\n<li>Chromosome <strong>10</strong> / <strong>RET gene</strong></li>\n<li>Associated conditions are:\n<ul>\n<li>Medullary Thyroid Carcinoma (90%)</li>\n<li>Pheochromocytoma (&gt;50%)</li>\n<li>Parathyroid adenoma (10&ndash;25%)</li>\n</ul>\n</li>\n</ul>\n<p><strong>MEN 2B</strong></p>\n<ul>\n<li>Known commonly as<strong> MEN 3</strong></li>\n<li>Chromosome<strong> 10/ RET gene</strong></li>\n<li>Associated conditions are:\n<ul>\n<li>Medullary Thyroid Carcinoma (&gt;90%)</li>\n<li>Pheochromocytoma (&gt;50%)</li>\n<li>Other associated abnormalities include: (40&ndash;50%)\n<ul>\n<li>Mucosal neuromas</li>\n<li>Marfanoid habitus</li>\n<li>Medullated corneal nerve fibers</li>\n<li>Megacolon</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a01742751e314b5fb189a29264e911d3x1280x1061.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: MEN 1 Syndrome Features</h3><p>Chromosome <strong>11q13 / MEN1 </strong>gene</p>\n<p>Also known as <strong>Wermer&rsquo;s syndrome</strong></p>\n<p>Characteristic tumors seen in:</p>\n<ul>\n<li>Parathyroid adenoma &ndash; 90 % - Most common overall</li>\n<li>Entero pancreatic tumors - Most common functioning tumor is gastrinoma (most common site is duodenum)</li>\n<li>Pituitary adenoma &ndash; Most common is prolactinoma</li>\n<li><strong>Mnemonic</strong> &ndash; Par Pan Pit &ndash; in decreasing order of frequency</li>\n</ul>\n<p>Associated tumors are:</p>\n<ul>\n<li>Angiofibroma</li>\n<li>Collagenomas</li>\n<li>Adrenal cortical tumors</li>\n<li>Lipoma</li>\n<li>Neuroendocrine tumors - gastric, thymic, lungs</li>\n<li>Meningioma</li>\n<li>Pheochromocytoma</li>\n<li>Carcinoid tumors, usually of the foregut</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/95f7c4eac7794f728806926c4f50bbb2x1280x1061.JPEG\" alt=\"Pearl Image\"><hr><h3>Related Pearl: MEN 4 Syndrome Features</h3><p>It is associated with CDKN1B gene on&nbsp;chromosome 12.</p>\n<p>Associated conditions:</p>\n<ul>\n<li>Parathyroid adenoma</li>\n<li>Pituitary adenoma</li>\n<li>Reproductive organ tumors like testicular cancer, neuroendocrine cervical carcinoma</li>\n<li>Adrenal and renal tumors</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0519",
      "difficulty": "medium"
    },
    {
      "text": "A 56-year-old woman coming from a hilly area presents a hard swelling in the neck which moves up with deglutition. The biopsy on the frozen section is given below. All of the following are true about this carcinoma, except that _____.",
      "choices": [
        {
          "id": 1,
          "text": "It is associated with RAS mutation."
        },
        {
          "id": 2,
          "text": "Hematogenous spread is common."
        },
        {
          "id": 3,
          "text": "It usually presents as solitary nodule."
        },
        {
          "id": 4,
          "text": "It can be diagnosed by FNAC."
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The clinical scenario of a patient from a <strong>hillyarea</strong> (iodine-deficient) and the biopsy specimen showing <strong>capsular invasion</strong> by tumor follicles confirms the diagnosis of <strong>follicular carcinoma</strong>. Follicular carcinoma cannot be diagnosed by FNAC.</p>\n<p><strong>FNAC cannot distinguish </strong>between<strong> follicular adenoma</strong> and<strong> follicular carcinoma</strong>. Capsular invasion must be present to diagnose follicular carcinoma, which can be seen only on biopsy.</p><hr><h3>Related Pearl: Follicular thyroid malignancy</h3><p>It is more common in <strong>iodine-deficient areas. </strong>It is associated with p53, PTEN, PAX/PPAR-gamma, RAS, miRNA (miR-197 and miR-346).</p>\n<p>It commonly presents as <strong>solitary thyroid nodules </strong>and the mean age of presentation is <strong>50 years.&nbsp;</strong>It can also occur in long-standing cases of multinodular goitre.</p>\n<p>FNAC&nbsp;is unable to distinguish between benign and malignant follicular lesions as <strong>malignancy</strong> is defined by <strong>capsular</strong> and <strong>vascular invasion. </strong>Hence, <strong>Trucut</strong> biopsy is required to confirm malignancy.</p>\n<p>Histological findings:</p>\n<ul>\n<li>Encapsulated</li>\n<li>Uniform microfollicles&nbsp;or sheets of cells devoid of colloid</li>\n<li>Capsular and vascular invasion indicates malignancy</li>\n<li>Tumour thrombus within middle thyroid/ jugular veins may be seen at the time of surgery</li>\n</ul>\n<p><strong>Vascular</strong> (hematogenous) dissemination is common, with metastases to bone, lungs, liver, and elsewhere. The prognosis depends largely on the extent of invasion and stage at presentation.</p>\n<p>Serum <strong>thyroglobulin</strong> levels are used for monitoring tumour recurrence, as they are undetectable after complete treatment.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/ebd9e706301c4520ae51e896062350e9.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0520",
      "difficulty": "medium"
    },
    {
      "text": "All the following are seen in ADHD except?",
      "choices": [
        {
          "id": 1,
          "text": "Impulsiveness"
        },
        {
          "id": 2,
          "text": "Delusions"
        },
        {
          "id": 3,
          "text": "Inattention"
        },
        {
          "id": 4,
          "text": "Hyperactivity"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>ADHD &ndash; Attention deficit hyperactive disorder.Is the most common psychiatric problem in school going age group. It is more common in boys than in girls. It is characterized by hyperactivity, impulsiveness and inattention. ADHD In children can lead to anti-social behaviour in the later ages.<br />Attention deficit hyperactive disorder</p>\n<p><strong>Diagnostic criteria:</strong></p>\n<p><strong>6 of the inattention symptoms for 6 months</strong></p>\n<ul>\n<li>Makes careless mistakes</li>\n<li>Difficulty in maintaining attention</li>\n<li>Do not listen</li>\n<li>Fails to follow instructions</li>\n<li>Avoids tasks and difficulty in organizing tasks</li>\n<li>Easily distracted and forgetful</li>\n</ul>\n<p><strong>6 or more symptoms of hyperactivity</strong></p>\n<ul>\n<li>Leaves seat</li>\n<li>Difficulty in playing and talks excessively</li>\n</ul>\n<p><strong>Symptoms of impulsivity</strong></p>\n<ul>\n<li>Difficulty awaiting turn</li>\n<li>Often interrupts</li>\n</ul>\n<p><strong>Treatment for ADHD</strong><br />The first line treatment is pharmacotherapy<br />a. CNS stimulants &ndash; methylphenidate, other drugs are- modafinil, atomoxetine, bupropion<br />b. Behavioral treatment and psychological treatment is given</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0521",
      "difficulty": "easy"
    },
    {
      "text": "Which among the following is the most common neoplasm of salivary gland?",
      "choices": [
        {
          "id": 1,
          "text": "Pleomorphic adenoma"
        },
        {
          "id": 2,
          "text": "Adenoid cystic carcinoma"
        },
        {
          "id": 3,
          "text": "Mucoepidermoid carcinoma"
        },
        {
          "id": 4,
          "text": "Mixed tumor"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<ul>\n<li>MC neoplasm of salivary gland : Pleomorphic adenoma</li>\n<li>MC neoplasm of salivary gland in children : Hemangioma</li>\n<li>MC malignant tumour of salivary gland : Mucoepidermoid carcinoma</li>\n<li>MC malignant tumour of salivary gland in children : Mucoepidermoid carcinoma</li>\n<li>MC malignant tumour of minor salivary glands : Adenoid cystic carcinoma</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0522",
      "difficulty": "easy"
    },
    {
      "text": "Primary peritonitis with pneumococcus is associated with which of the following",
      "choices": [
        {
          "id": 1,
          "text": "Lymphomas"
        },
        {
          "id": 2,
          "text": "Nephrotic syndrome"
        },
        {
          "id": 3,
          "text": "Carcinoids"
        },
        {
          "id": 4,
          "text": "None of the above"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<ul>\n<li>Primary pneumococcal peritonitis may complicate <strong>nephrotic syndrome or cirrhosis in children.</strong></li>\n<li>Otherwise healthy children particularly girls between 3-9 years may also be affected, route of infection is via vagina and fallopian tubes.</li>\n<li>Always in males, infection is blood-borne and secondary to respiratory tract or middle ear disease.<br /> <strong>Clinical features:</strong></li>\n<li>Sudden onset<strong> pain</strong> in lower abdomen.</li>\n<li><strong>Temperature</strong> as high as 39 degrees celsius or higher.</li>\n<li>After 1-2 days, profuse <strong>diarrhoea,</strong> increased frequency of micturition (due to severe pelvic peritonitis)</li>\n<li>On examination, <strong>abdominal rigidity</strong><br /> <strong>Diagnosis</strong>:</li>\n<li>WBC count more than 30,000/microlitre with approximately 90% polymorphs suggests pneumococcal peritonitis.</li>\n<li><strong>If exudate is odourless and sticky, the diagnosis of pneumcoccal peritonitis is certain</strong><br /> <strong>Treatment:</strong></li>\n<li>Antibiotic treatment + correcting dehydration and electrolyte imbalance+ early surgery</li>\n<li>laparotomy or laparoscopy</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0523",
      "difficulty": "medium"
    },
    {
      "text": "GH is produced by which cells of pituitary?",
      "choices": [
        {
          "id": 1,
          "text": "Acidophil"
        },
        {
          "id": 2,
          "text": "Basophil"
        },
        {
          "id": 3,
          "text": "Neutrophil"
        },
        {
          "id": 4,
          "text": "Theca cell"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>GH is produced by acidophil Five types of secretory cells have been identified in the anterior pituitary by immunocytochemistry and electron microscopy. The cell types are</p>\n<p>&bull;&nbsp;&nbsp;&nbsp; The somatotropes, which secrete growth hormone;</p>\n<p>&bull;&nbsp;&nbsp;&nbsp; The lactotropes (also called mammotropes), which secrete prolactin;</p>\n<p>&bull;&nbsp;&nbsp;&nbsp; The corticotropes, which secrete ACTH;</p>\n<p>&bull;&nbsp;&nbsp;&nbsp; The thyrotropes, which secrete TSH; and</p>\n<p>&bull;&nbsp;&nbsp;&nbsp; The gonadotropes, which secrete FSH and LH.</p>\n<table>\n<tbody>\n<tr>\n<td>Cell type</td>\n<td>Hormones Secreted</td>\n<td>% of total secretory cells</td>\n</tr>\n<tr>\n<td>Somatotrope</td>\n<td>Growth hormone</td>\n<td>50</td>\n</tr>\n<tr>\n<td>Lactotrope</td>\n<td>Prolactin</td>\n<td>10-30</td>\n</tr>\n<tr>\n<td>Corticotrope</td>\n<td>ACTH</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Thyrotrope</td>\n<td>TSH</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Gonadotrope</td>\n<td>FSH, LH</td>\n<td>20</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Some cells may contain two or more hormones. It is also notable that the three pituitary glycoprotein hormones, FSH, LH, and TSH, while being made up of two subunits, all share a common &alpha; subunit that is the product of a single gene and has the same amino acid composition in each hormone, although their carbohydrate residues vary. The &beta; subunits, which are produced by separate genes and differ in structure, confer hormonal specificity. Somatotropes and lactotrophs stain strongly with acid dyes and are therefore called acidophils. Thus, pituitary tumors that secrete large quantities of human growth hormone are called acidophilic tumors. The rest of the cells are basophils.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0524",
      "difficulty": "easy"
    },
    {
      "text": "Barton's fracture is",
      "choices": [
        {
          "id": 1,
          "text": "Fracture distal end of humerus"
        },
        {
          "id": 2,
          "text": "Extra articular fracture distal end of radius"
        },
        {
          "id": 3,
          "text": "Intra-articular fracture distal end of radius"
        },
        {
          "id": 4,
          "text": "Intra- articular fracture of distal end of radius with carpal bone subluxation"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Bartons fracture</strong> is Intra- articular fracture of distal end of radius with carpal bone subluxation.</p><p>Mechanism Of Injury: fall on flexed wrist with dorsiflexion and pronation of distal forearm.</p>\n<p><br /><strong>Clinical features:</strong></p>\n<ul>\n<li>Pain</li>\n<li>Swelling</li>\n<li>Tenderness</li>\n<li>Restriction of wrist movements with painful dorsiflexion.</li>\n</ul>\n<p><strong>Radiograph:</strong><br />Best seen on the lateral view, the dorsal tip of distal radial articular surface is displaced proximally and posteriorly and may be associated with dorsal subluxation of the wrist.</p>\n<p><strong>Treatment:</strong></p>\n<ul>\n<li>Conservative - short arm cast with the wrist in neutral position.</li>\n<li>Surgery - unstable fracture is fixed by percutaneous pins or small screws. Open Reduction +Internal Fixation with small plate and screws can be done.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0525",
      "difficulty": "medium"
    },
    {
      "text": "The velocity of conduction of impulse is maximum in the?",
      "choices": [
        {
          "id": 1,
          "text": "Atrium"
        },
        {
          "id": 2,
          "text": "SA node"
        },
        {
          "id": 3,
          "text": "AV node"
        },
        {
          "id": 4,
          "text": "Purkinje fibers"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The velocity of conduction is maximum in the <strong>Purkinje fibers,</strong> which is <strong>4 meters/sec</strong>. The table below shows the conduction velocities in different cardiac structures. &nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Tissue</strong></td>\n<td><strong>Conduction rate(m/s)</strong></td>\n</tr>\n<tr>\n<td>SA node</td>\n<td>0.05</td>\n</tr>\n<tr>\n<td>Atrial pathways</td>\n<td>1</td>\n</tr>\n<tr>\n<td>AV node</td>\n<td>0.05</td>\n</tr>\n<tr>\n<td>Bundle of His</td>\n<td>1</td>\n</tr>\n<tr>\n<td>Purkinje system</td>\n<td>4</td>\n</tr>\n<tr>\n<td>Ventricular muscle</td>\n<td>1</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0526",
      "difficulty": "medium"
    },
    {
      "text": "In otosclerosis during stapes surgery prosthesis used is",
      "choices": [
        {
          "id": 1,
          "text": "Teflon piston"
        },
        {
          "id": 2,
          "text": "Grommet"
        },
        {
          "id": 3,
          "text": "Total ossicular replacement"
        },
        {
          "id": 4,
          "text": "All"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<ul>\n<li><strong>Teflon piston</strong> is used as prosthesis for stapes in <strong>otosclerosis surgery.</strong></li>\n<li><strong>Grommet insertion</strong> is required in <strong>serous otitis media.</strong></li>\n<li><strong>Total ossicular replacement prosthesis (TORP)</strong> is used when it is required to<strong> reconstruct whole of the ossicular chain</strong> for example in unsafe CSOM when there occurs complete necrosis of all the three ossicles.&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0527",
      "difficulty": "medium"
    },
    {
      "text": "Identify the below image",
      "choices": [
        {
          "id": 1,
          "text": "Bacterial keratitis"
        },
        {
          "id": 2,
          "text": "Fungal keratitis"
        },
        {
          "id": 3,
          "text": "Acanthamoeba keratitis"
        },
        {
          "id": 4,
          "text": "Simplex keratitis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The image depicts a bacterial corneal ulcer with hypopyon. The ulcer is round to oval in shape which is highly characteristic of the bacterial corneal ulcer.&nbsp;</p>\n<p>The organism causing the ulcer can only be confirmed by culture. In this question, only the image is provided. Hence, the best answer to this question is a bacterial corneal ulcer. Keratitis is inflammation of the cornea. Symptoms include pain, lacrimation, photophobia, blepharospasm, and varying degrees of diminution of vision.&nbsp;</p>\n<p><strong>Bacterial keratitis</strong></p>\n<ul>\n<li>Fluorescein stains positive for ulcer</li>\n<li><strong>Sterile</strong> hypopyon.</li>\n<li>Hypopyon is fluid and mobile</li>\n</ul>\n<p><strong>Treatment of bacterial keratitis</strong></p>\n<div class=\"ng-star-inserted\">\n<div class=\"table-responsive font-weight-light answer-scroll answer-html ng-star-inserted\">\n<ul>\n<li>Antibiotic eyedrops &ndash; broad-spectrum antibiotics</li>\n<li>Antibiotic ointment at night</li>\n<li>If not responding fortified antibiotic eyedrops are used Fortified cephazolin (5%), Fortified tobramycin (1.3%), Fortified vancomycin (5%)</li>\n<li>Oral vit A and C- help in the healing of epithelium Systemic analgesics and anti-inflammatory drugs.</li>\n</ul>\n</div>\n</div>\n<div class=\"row mt-3\">\n<div class=\"col-auto\">&nbsp;</div>\n</div>\n<p><strong>Option B:&nbsp;</strong>Fungal corneal ulcer has feathery borders, satellite lesions, and necrotic slough.</p>\n<p><strong>Option C: </strong>Acanthamoeba keratitis shows irregularity and multifocal infiltration, pseudo dendrites, or elevated epithelial ridges.</p>\n<p><strong>Option D:</strong> Simplex keratitis shows a coarse punctate or stellate pattern of swollen opaque epithelial cells, a dendritic ulcer with terminal buds.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d30f4d8dde7849f786c7772121d23e81.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0528",
      "difficulty": "hard"
    },
    {
      "text": "Laryngeal crepitus is absent in all of the following except",
      "choices": [
        {
          "id": 1,
          "text": "Post-cricoid malignancy"
        },
        {
          "id": 2,
          "text": "Hypopharyngeal abscess"
        },
        {
          "id": 3,
          "text": "Parapharyngeal abscess"
        },
        {
          "id": 4,
          "text": "Prevertebral abscess"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Any condition<strong> behind the cricoid</strong> e.g. <strong>postcricoid malignancy or in front of the vertebra e.g. prevertebral or retropharyngeal abscess</strong> (<strong>hypo pharyngeal abscess</strong>) will lead to <strong>absent laryngeal crepitus</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0529",
      "difficulty": "hard"
    },
    {
      "text": "What is the principal antigen which is implicated in Pemphigus Vulgaris?",
      "choices": [
        {
          "id": 1,
          "text": "Desmoglein 1"
        },
        {
          "id": 2,
          "text": "Desmoglein 3"
        },
        {
          "id": 3,
          "text": "Desmoglein 2"
        },
        {
          "id": 4,
          "text": "Desmoplakin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Pemphigus Vulgaris is an immunobullous disease or a chronic blistering disease which occurs due to an autoimmune process by the production of antibodies against desmosomes(adhesion proteins). In Pemphigus Vulgaris, desmoglein 3 is the principal antigen. Desmoglein 1 and Desmocollins are also implicated.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0530",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is true with respect to Rajiv Gandhi Shramik Kalyan Yojna?",
      "choices": [
        {
          "id": 1,
          "text": "50% of daily wage for 24 months"
        },
        {
          "id": 2,
          "text": "50% daily wages for 6 months"
        },
        {
          "id": 3,
          "text": "70%daily wages for 6 months"
        },
        {
          "id": 4,
          "text": "70% daily wages for 24 months"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>In Rajiv Gandhi shramik kalyan yojna</p>\n<ul>\n<li>The allowance is given at the rate of 50% of daily wage a maximum of 24 months.</li>\n<li>This scheme provides <strong>unemployment allowance</strong> to those insured people who have been involuntarily thrown out of employment due to recession or retrenchment.</li>\n<li>To qualify for the scheme the worker <strong>must have worked in that setup for 3 years or more.</strong></li>\n</ul>\n<p><strong>Note: </strong>Park mentions 50% of daily wage for 6 months, the government has changed it to 24 months. Eligibility&nbsp;payment period has also been reduced&nbsp;period from 5 to 2 years.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0268",
      "difficulty": "hard"
    },
    {
      "text": "Bird beak appearance in barium swallow is seen in",
      "choices": [
        {
          "id": 1,
          "text": "Achalasia cardia"
        },
        {
          "id": 2,
          "text": "Diffuse esophageal spasm"
        },
        {
          "id": 3,
          "text": "Ca esophagus"
        },
        {
          "id": 4,
          "text": "Duodenal atresia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Achalasia is a <strong>primary esophageal motility disorder</strong> characterized by the <strong>absence of esophageal peristalsis</strong> and<strong> impaired relaxation of the lower esophageal sphincter (LES)</strong> in response to swallowing. The LES is hypertensive in about 50% of patients. These abnormalities cause a functional obstruction at the gastro-esophageal junction (GEJ).</p>\n<p>Radiographically, the esophagus is often<strong> dilated</strong>, and a standing column of contrast material is seen. <strong>Fixed, smooth narrowing is present in distal esophagus</strong>. Periodic relaxation of the lower esophageal sphincter with continued drinking is a critical observation for distinguishing primary achalasia from pseudoachalasia&mdash;carcinoma of the gastroesophageal junction (a fixed, nonrelaxing obstruction).</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/42e445d39be44a06821b58867253efd3x281x595.PNG\" alt=\"Explanation Image\"><p>The above image depicts a dilated esophagus with retained column of barium and &ldquo;bird&rsquo;s beaking&rdquo; suggestive of achalasia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0531",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following investigation is shown in the radiograph?",
      "choices": [
        {
          "id": 1,
          "text": "Barium swallow"
        },
        {
          "id": 2,
          "text": "Barium meal"
        },
        {
          "id": 3,
          "text": "Barium enema"
        },
        {
          "id": 4,
          "text": "Enteroclysis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The above radiograph shows a <strong>Barium meal</strong>. (The condition depicted is trichobezoar which shows a filling defect in a barium meal X-ray)</p>\n<p>Barium is used as a contrast for <strong>GI imaging.</strong></p>\n<p><strong>Contraindications</strong> to use of Barium:</p>\n<ul>\n<li><strong>Tracheo esophageal fistula</strong>: Dianosil-water soluble non-ionic agent is used</li>\n<li><strong>Perforation peritonitis</strong>: Gastrograffin-Ionic water soluble agent is used</li>\n</ul>\n<p><strong>Procedures</strong>: For Single contrast films barium alone is used. Double contrast films requires air and barium which is better for small mucosal lesion.</p>\n<ul>\n<li>Ba swallow uses barium paste (for <strong>esophagus</strong>)</li>\n<li>Ba meal- 95% BaSO4 (for <strong>stomach and duodenum</strong>)</li>\n<li>Ba meal follow through -50% BaSO4 (for <strong>small bowel</strong>)</li>\n<li>Ba enema -25% BaSO4 (for <strong>large bowel)</strong></li>\n</ul>\n<p><strong>Enteroclysis</strong> -&nbsp;gastrointestinal technique designed to provide improved evaluation of the&nbsp;<strong>small bowel</strong> from jejunum to ileocecal junction. It is done by intubating the jejunum and instillation of the contrast material through the tube.</p>\n<p>The conventional fluoroscopic technique is not widely used since it is somewhat invasive, time and labour intensive, and not particularly pleasant for the patient.&nbsp;Modifications of the tradition technique may involve CT or MRI. It is indicated for examination of mucosal detail of the small intestine and <strong>improved evaluation of small bowel</strong> tumours or inflammatory disease.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d65a37e8368e41e8ac55149e21c76892.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA0532",
      "difficulty": "medium"
    }
  ]
}